4SC AG EV / EBITDA
Cos'è EV / EBITDA di 4SC AG?
EV / EBITDA di 4SC AG è 0.60
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su XETRA rispetto a 4SC AG
Cosa fa 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Aziende con ev / ebitda simili a 4SC AG
- Satsuma Pharmaceuticals ha EV / EBITDA di 0.59
- QPL International ha EV / EBITDA di 0.59
- Cobra Venture ha EV / EBITDA di 0.59
- Unico American ha EV / EBITDA di 0.59
- Questerre ha EV / EBITDA di 0.60
- AHAlife ha EV / EBITDA di 0.60
- 4SC AG ha EV / EBITDA di 0.60
- Guangnan () ha EV / EBITDA di 0.61
- Enveric Biosciences ha EV / EBITDA di 0.61
- FibroGen Inc ha EV / EBITDA di 0.61
- Silverback Therapeutics ha EV / EBITDA di 0.61
- Billing Services ha EV / EBITDA di 0.61
- STM Plc ha EV / EBITDA di 0.61